P76.85 Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors

Authors
Category Primary study
JournalJournal of Thoracic Oncology
Year 2021
This article has no abstract
Epistemonikos ID: c76241b5a4c1d933faa8105a1e7f25830656aea5
First added on: Feb 12, 2025